J.ophthalmol.(Ukraine).2019;5:27-29.
http://doi.org/10.31288/oftalmolzh201952729
Received: 04 September 2019; Published on-line: 30 October 2019
Changes in the expression of molecular markers of peripheral blood lymphocyte activation in patients with small (T1) choroidal melanoma after transpupillary thermotherapy
I.V. Tsukanova, Junior Research Associate; S.I. Poliakova, Dr Sc (Med); L.M. Velichko, Dr Sc (Med); O.V. Bogdanova, Cand Sc (Med)
Filatov Institute of Eye Diseases and Tissue Therapy, NAMS of Ukraine; Odesa (Ukraine)
E-mail: inna.sister@gmail.com
TO CITE THIS ARTICLE: Tsukanova IV, Poliakova SI, Velichko LM, Bogdanova OV. Changes in the expression of molecular markers of peripheral blood lymphocyte activation in patients with small (T1) choroidal melanoma after transpupillary thermotherapy. J.ophthalmol.(Ukraine).2019;5:27-29. http://doi.org/10.31288/oftalmolzh201952729
Background: Expression of some functional molecules on peripheral blood lymphocytes is critically important for the development of adequate antitumor response.
Purpose: To investigate changes in the expression of molecular markers of peripheral blood lymphocyte activation in patients with small (T1) choroidal melanoma (CM; measuring ? 3 mm in protrusion into the vitreous and ? 12 mm in basal dimension) after transpupillary thermotherapy (TTT) delivered using our methodology.
Materials and Methods: We investigated the expression of molecular markers (СD7+, CD25+, CD38+, CD45+, CD54+, CD95+, CD150+) of peripheral blood lymphocyte activation using the routine methodology in 16 patients (12 women (75%) and 4 men (25%); mean age, 55.4 years (11.2 years)) with small (T1) CM at baseline and after a course of TTT delivered using our methodology. Statistical analyses were conducted using Statistica 10 (StatSoft, Tulsa, OK, USA) software.
Results: Four-day activity of all examined peripheral blood lymphocyte subpopulations in patients was observed in response to the curative effect of 810-nm diode laser TTT on CM. However, statistically significant increases were found only for the expression of the costimulatory molecule inducing cytokine secretion (CD7+) and proaptotic lymphocyte activity due to an increased share of CD95+-phenotype cells.
Conclusion: The expression of molecular markers of peripheral blood lymphocyte activation, especially the expression of the costimulatory molecule inducing cytokine secretion (CD7+) and proaptotic lymphocyte activity due to an increased share of CD95+-phenotype cells, increases within the course of TTT for the small (T1) CM.
Keywords: choroidal melanoma, transpupillary thermotherapy, molecular markers of peripheral blood lymphocyte activation
References
1.Rabson A, Rott IM, Delves PJ. [Really essential medical immunology]. Moscow:Binom; 2006. Russian.
2.Poliakova SI, Velichko LM, Bogdanova OV, Tsukanova IV. Comparison of expression of molecular markers of peripheral blood lymphocyte activation in patients with small uveal melanoma and healthy controls. J Ophthalmol (Ukraine). 2017;1:25-8. Russian.
3.Information Bulletin No. 22, based on Pat. of Ukraine №102,890 issued 25.11.2015. Method for treatment of T1 choroidal melanoma. Authors: Pasyechnikova NV, Naumenko VO, Poliakova SI, Tsukanova IV. Owner: State Institution Filatov Institute of Eye Diseases and Tissue Therapy, NAMS of Ukraine. Ukrainian.
4.Gluzman DF, Skliarenko LM, Nadgornaia VA, Kriachok IA. [Immunocytochemistry in tumor diagnosis]. Kyiv: Morion;2003. Russian.
5.Velichko LN. [The level of activated lymphocytes molecular markers expression in peripheral blood in patients with uveal melanoma in varying efficiency preserving therapy]. Oftalmol Zh. 2013; 5:9-13. Russian.
6.Berezhnaia NM. [Interleukin system and cancer (new aspects of the interaction between the tumor and the body]. Kyiv:DIA; 2000. Russian.
7.Berezhnaia NM, Chekhun VF. [Immunology of malignant growth]. Kyiv: Naukova Dumka; 2005. Russian.
8.Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 Apr;6(4):345-52.
The authors certify that they have no conflicts of interest in the subject matter or materials discussed in this manuscript.